In drug discovery and development, in vitro absorption
and metabolism
assays along with in vivo pharmacokinetic (PK), pharmacodynamic (PD),
and toxicokinetic (TK) studies are used to evaluate a potential drug
candidate. More recently, imaging mass spectrometry approaches have
been successfully reported to aid in the preclinical assessment of
drug candidates, resulting in the rapid and noteworthy acceptance
of the technique in pharmaceutical research. Traditionally, drug distribution
studies via mass spectrometric imaging (MSI) are performed as targeted
MS/MS analyses, where the analytes of interest, drug and/or metabolite,
are known before the imaging experiment is performed. The study presented
here describes a whole-body mass spectrometric imaging (WB-MSI) approach
using a hybrid MALDI-LTQ-Orbitrap-MS to detect the distribution of
reserpine at 2 h post a 20 mg/kg oral dose. This study effectively
demonstrates the utility of obtaining accurate mass measurements across
a wide mass range combined with postprocessing tools to efficiently
identify drug and metabolite distributions without the need for any
a priori knowledge.